Kopecky SL, Gersh BJ, McGoon MD.
et al. Lone atrial fibrillation in elderly persons: a marker for cardiovascular
risk. Arch Intern Med.1999;159:1118-1122.
Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial
fibrillation. Arch Intern Med.1994;154:1449-1157.
Stroke Prevention Atrial Fibrillation III Writing Committee. Patients with nonvalvular atrial fibrillation at low risk of stroke
during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III
Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation, I: clinical features
of patients at risk. Ann Intern Med.1992;116:1-5.
van Latum JC, Koudstaal PJ, Venables GS, van Gijn J, Kappelle LJ, Algra A.for the European Atrial Fibrillation Trial (EAFT) Study Group. Predictors of major vascular events in patients with a transient ischemic
attack or minor ischemic stroke and with nonrheumatic atrial fibrillation. Stroke.1995;26:801-806.
Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation:
a meta-analysis. Ann Intern Med.1999;131:492-501.
The European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient
ischaemic attack or minor stroke. Lancet.1993;342:1255-1262.
Laupacis A, Boysen G, Connolly S.
et al. The efficacy of aspirin in patients with atrial fibrillation: analysis
of pooled data from 3 randomized trials. Arch Intern Med.1997;157:1237-1240.
Gage BF, Cardinalli AB, Albers GW, Owens DK. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke
in patients with nonvalvular atrial fibrillation. JAMA.1995;274:1839-1845.
Laupacis A, Albers G, Dalen J, Dunn MI, Jacobson AK, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest.1998;114:579S-589S.
Go AS, Hylek EM, Phillips KA.
et al. Implications of stroke risk criteria on the anticoagulation decision
in nonvalvular atrial fibrillation: the anticoagulation and risk factors in
the Atrial Fibrillation (ATRIA) study. Circulation.2000;102:11-13.
Hart RG. Warfarin in atrial fibrillation: underused in the elderly, often inappropriately
used in the young [editorial]. Heart.1999;82:539-540.
Pearce LA, Hart RG, Halperin JL. Assessment of three schemes for stratifying stroke risk in patients
with nonvalvular atrial fibrillation. Am J Med.2000;109:45-51.
Atrial Fibrillation Investigators. Echocardiographic predictors of stroke in patients with atrial fibrillation:
a prospective study of 1066 patients from 3 clinical trials. Arch Intern Med.1998;158:1316-1320.
Stroke Prevention in Atrial Fibrillation Investigators. Risk factors for thromboembolism during aspirin therapy in patients
with atrial fibrillation: The Stroke Prevention in Atrial Fibrillation study. J Stroke Cerebrovasc Dis.1995;5:147-157.
Sudlow M, Thomson R, Thwaites B, Rodgers H, Kenny RA. Prevalence of atrial fibrillation and eligibility for anticoagulants
in the community. Lancet.1998;352:1167-1171.
Harrell Jr FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating
assumptions and adequacy, and measuring and reducing errors. Stat Med.1996;15:361-387.
Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW.for The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Factors associated with ischemic stroke during aspirin therapy in atrial
fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. Stroke.1999;30:1223-1229.
Feinberg WM, Kronmal RA, Newman AB.
et al. Stroke risk in an elderly population with atrial fibrillation. J Gen Intern Med.1999;14:56-59.
D'Agostino RB, Wolf PA, Belanger AJ, Kannel WB. Stroke risk profile: adjustment for antihypertensive medication: the
Framingham Study. Stroke.1994;25:40-43.
Flegel KM, Hanley J. Risk factors for stroke and other embolic events in patients with non-rheumatic
atrial fibrillation. Stroke.1989;20:1000-1004.
Yuan Z, Bowlin S, Einstadter D, Cebul R, Conners A, Rimm A. Atrial fibrillation as a risk factor for stroke: a retrospective cohort
study of hospitalized Medicare beneficiaries. Am J Public Health.1998;88:395-400.
Stroke Prevention in Atrial Fibrillation Investigators. Predictors of thromboembolism in atrial fibrillation, II: Echocardiographic
features of patients at risk. Ann Intern Med.1992;116:6-12.
Moulton AW, Singer DE, Hass JS. Risk factors for stroke in patients with nonrheumatic atrial fibrillation:
a case-control study. Am J Med.1991;91:156-161.
Jencks SF, Wilensky GR. The Health Care Quality Improvement Initiative: a new approach to quality
assurance in Medicare. JAMA.1992;268:900-903.
Benesch C, Witter DMJ, Wilder AL, Duncan PW, Samsa GP, Matchar DB. Inaccuracy of the International Classification of
Diseases (ICD-9-CM) in identifying the diagnosis
of ischemic cerebrovascular disease. Neurology.1997;49:660-664.
Lee E. Statistical Methods for Survival Data Analysis. 2nd ed. New York, NY: John Wiley & Sons; 1992.
Allison PD. Survival Analysis Using the SAS System: A Practical
Guide. Cary, NC: SAS Institute Inc; 1995.
Rothman KJ, Greenland S. Modern Epidemiology. 2nd ed. Philadelphia, Pa: Lippincott-Raven Publishers; 1998.
Mooney CZ, Duval RD. Bootstrapping: A Nonparametric Approach to Statistical
Inference. Newbury Park, Calif: Sage Publications Inc; 1993.
Stroke Prevention in Atrial Fibrillation Investigators. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus
aspirin for high-risk patients with atrial fibrillation: Stroke Prevention
in Atrial Fibrillation III randomised clinical trial. Lancet.1996;348:633-638.
Hellemons BS, Langenberg M, Lodder J.
et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial
fibrillation in primary care: randomised controlled trial comparing two intensities
of coumarin with aspirin. BMJ.1999;319:958-964.
Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med.1997;336:1506-1511.
Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin
on quality of life. Arch Intern Med.1996;156:1829-1836.
Howitt A, Armstrong D. Implementing evidence based medicine in general practice: audit and
qualitative study of antithrombotic treatment for atrial fibrillation. BMJ.1999;318:1324-1327.
Gage BF, Cardinalli AB, Owens DK. Cost-effectiveness of preference-based antithrombotic therapy for patients
with nonvalvular atrial fibrillation. Stroke.1998;29:1083-1091.
Man-Son-Hing M, Laupacis A, O'Connor AM.
et al. A patient decision aid regarding antithrombotic therapy for stroke
prevention in atrial fibrillation: a randomized controlled trial. JAMA.1999;282:737-743.
Foulkes MA, Sacco RL, Mohr JP, Hier DB, Price TR, Wolf PA. Parametric modeling of stroke recurrence. Neuroepidemiology.1994;13:19-27.